Address for Correspondence: Taalaibek Kudaiberdiev,
Scientific Research Institute of Heart Surgery and Organ Transplantation, Togolok Moldo St 3, Bishkek, Kyrgyzstan, E-mail: email@example.com
In this review, we summarized current evidence on clinical significance, outcomes and management of postpericardiotomy syndrome and its complications developing after cardiac operations.
Key words: heart surgery, pericardium, postpericardiotomy syndrome, outcomes, management
Postpericardiotomy syndrome (PPS) occurs in about 15-30% of patients undergoing cardiac surgery (1-6, 7). It is defined in presence of 2 of 5 criteria: 1) fever occurring at least one week after surgery without underlying infection 2) pleuritic pain, 3) pericardial rub 4) pleural effusion and 5) pericardial effusion (8). Another research group, proposed more detailed definition of PPS, to minimize false-positive diagnosis providing details on the size of pleural and pericardial effusion and fever (7). In their definition, PPS is diagnosed in presence of 2 of the following criteria: pericardial rubbing, fever >72 hours postoperative, pleuritic chest pain, new significant pleural effusion on chest radiograph (above the highest level of the diaphragm), or significant pericardial effusion (10 mm). The ESC 2015 guidelines definition of PPS is under umbrella of post-cardiac injury syndrome, a group of inflammatory pericardial syndromes that include post-myocardial infarction Dressler pericarditis, PPS and post-cardiac trauma (9).Postcardiac injury syndrome is diagnosed when at least 2 of 5 criteria met: 1) fever without alternative causes, 2) pericarditic or pleuritic chest pain, 3) pericardial or pleural effusion, 4) evidence of pericardial effusion and/or pericardial effusion with elevation of C-reactive protein. PPS can manifest as acute pericarditis as well (10). The main complications of PPS are development of tamponade and constrictive pericarditis (1-6). Tamponade complicates PPS in 6.4% and constrictive pericarditis in 2-3% of patients (11, 12).
We aimed to summarize current evidence on prevalence, clinical significance, outcomes and management of postpericardiotomy syndrome developing after cardiac surgery and its complications – tamponade and constrictive pericarditis.Constrictive pericarditis after cardiac surgery
Constrictive pericarditis develops in 2-3% of patients undergoing cardiac surgery (11). It usually develops late after surgery (3-56 months) and has manifestations of dyspnea and right-sided heart failure. It is thought that pooling of blood after surgery in pericardial sac, inflammation and development of fibrosis can cause the thickening and adhesions in pericardium.
One of the earliest series of cases with constrictive pericarditis after cardiac surgery and its treatment was described by Killian et al. (13). Their study included 45 patients with median age of 61 years, majority of them (33 patients) underwent coronary bypass surgery (CABG), among them 4 patients had history of 2 or more surgeries. Constrictive pericarditis developed during median 23 months (1-204 months) after surgery. Mean pericardial thickening on computed tomography was 0.8 mm. There were signs of inflammation, fibrosis and calcification of pericardium intraoperatively. Pericardial stripping (subtotal pericardioectomy) was performed in 37 patients and 8 patients were treated medically. Overall, 28 patients had symptomatic improvement after surgery, 4 patients underwent extensive pericardioectomy. Mortality rate after surgery was 11% - 4 patients died during 30 days after pericardioectomy
Another series from Emory hospital were described by Kutcher et al. (14). Among 5207 patients undergoing cardiac surgery, 11 patients developed PPS (0.2%) during median 82 days (4-186 days) after cardiac surgery. Seven of patients had thickening of pericardium and 4 patients had both thickening and effusion. Pericardium was left open during surgery in all patients. Irrigation of pericardium with povidone-iodine solution was performed in 5 patients, with antibiotics in 2 patients and with cold saline in 4 patients. Three patients showed symptomatic relief after medical therapy, among them 1 patient underwent further removal of hematoma and 8 patients underwent radical pericardioectomy. Five patients had acute right heart overload. Six patients had STT abnormalities and 3 patients had low QRS voltage on electrocardiogram (ECG), 7 patients had paradoxal interventricular septal movement on echocardiogram and 5 patients had effusion postoperatively including 4 patients with hematoma of pericardium at posterior wall, and 10 patients had classical signs of constriction on cardiac catheterization with equalization of right ventricular, right atrial, pulmonary capillary wedge and left ventricular pressures. The standard protocol included 2-8 weeks of medical treatment with diuretic, non-steroidal anti-inflammatory agents (NSAIDs) and corticosteroids, 3 patients had symptomatic improvement and 8 patients underwent pericardioectomy. Analysis of 3 patients who had relief of symptoms on medical therapy demonstrated late cardiac tamponade or sero-effusive constriction without true fibrosis in 1 case, less advanced fibrosis with reversible sero-effusive component in 2nd case and localized pericardial hematoma that was removed during reoperation for main indication of valvular heart disease (VHD) in 1 patient. Analysis of 8 patients who underwent pericardioectomy demonstrated extensive parietal and visceral hemorrhagic pericardial fibrosis and organization in 4 patients with inflammatory hemorrhagic fibrinous deposits. Authors concluded that almost all patients had pericardial fluid accumulation after cardiac surgery, but symptoms developed only in 15-30% of patients and despite treatment 0.2% of patients developed constrictive pericarditis.
The most recent series were reported from Cleveland clinic (15). This prospective cohort study included 239 patients with PPS after cardiac surgery (7), primary endpoints of the study were development of effusion and constriction during follow-up of 12 months. Overall 75 patients (31%) required intervention: 44 patients with pericardial effusion and tamponade, including 22 patients who underwent pericardiocentesis and 24 – subxiphoid pericardiostomy with drainage, and 31 patients – pericardioectomy. Patients had increased levels of C-reactive protein and sedimentation rate, 14% of them had right heart failure and 31% - signs of constriction. Multivariable analysis demonstrated that constriction physiology as well as younger age, and heart failure signs increased risk of PPS and constriction development during follow-up by almost 6 times, while use of colchicine therapy and NSAIDS reduced risk of tamponade and constriction by 55% (HR – 0.45, 95%CI 0.26-0.79). In younger patients with PPS with signs of heart failure and constrictive physiology, early appropriate management seems to be warranted.
Predictors and outcomes of PPS
Several studies described predictors of PPS development after heart surgery. Analysis of COPPS prospective randomized double blind trial (1) on efficacy of colchicine after cardiac surgery for prevention of PPS included 360 patients randomized for placebo and colchicine. Among them 15% developed PPS, with 79.6% during 1st months after cardiac surgery, 13% - 2 months and 7.4% - 3 months. During follow-up tamponade was observed in 1.9% of patients, readmission in 19.8%, and PPS relapse in 3.7% of patients. Risk of unfavorable outcomes development was 2.32 times higher in patients with renal failure and 4.31 times higher in patients with pleural incision.
FinPPS study (16) included 688 patients undergoing CABG surgery, among them PPS developed in 61 patients (8.9%) during median 21 days (1-52 days) of follow-up. Interventions were required in 13 patients (22%) – pleural drainage and 3 patients (4.9%) underwent pericardiocentesis. Patients with PPS more often received blood transfusion but had less diabetes (HR 0.32 95% CI 0.15-0.71, p=0.005) and were less treated with metformin. Recurrence developed in 38%. Predictors of PPS were blood transfusion >1 unit (HR 1.9 95%CI 1.1-3.2, p=0.017) and renal insufficiency, while independent predictor of recurrence was increased body mass index. Patients who developed relapse of PPS also had shorter hospital stay and more pleural punctions. In this study, bleeding played major role in patients undergoing CABG in development of PPS, and surprisingly diabetes played protective role.
Another study (7) that included 822 patients undergoing cardiac valve surgery addressed the risk factors and primary (1-year reoperation rate due to tamponade) and secondary (hospital stay duration and mortality) outcomes in patients who developed PPS after cardiac surgery. Overall 14.5% of patients developed PPS. Patients with high body mass index (OR 0.94, 95%CI 0.89-0.99) had low risk of PPS, while preoperative treatment for chronic obstructive pulmonary disease without corticosteroids was associated with 2.55 fold (95%CI 1.25-5.2) increased risk of PPS development. Patients with PPS had high risk of re-operation for tamponade (20.9% vs 2.5% (OR-15.49, 95%CI 7.44-33.58), longer in-hospital stay (13 days vs 11 days, p=0.001), but no difference in mortality rate (4.2% vs.5.5 %) as compared to group of patients without PPS.
In our series (17), we detected development of PPS in 15.5%, complicated by tamponade in 10% and constrictive pericarditis in 5% of patients.
Recent systematic review demonstrated that the risk of PPS is associated with young age of patients, requirement for red blood cells transfusion, and low preoperative platelet and hemoglobin levels (18).
Thus, patients with bleeding, low level of platelets and hemoglobin, requiring red blood cells transfusion, pleural punctions, preoperative history of treatment for chronic obstructive pulmonary disease, renal failure, are more prone to develop PPS after cardiac surgery. Overall, the PPS is associated with high-risk of tamponade development; however, the prognosis is good with no difference in mortality as compared to patients without PPS.
Mechanisms of PPS and its complications development after cardiac surgery
Several mechanisms responsible for development of PPS have been described. It is thought that spilled blood, bleeding and its contact with serosal surface has an irritating effect inducing thrombosis, inflammation and fibrosis. It was observed that intraoperative bleeding is associated with development of adhesions and fibrosis leading to constrictive pericarditis (19).
One of the frequent causes of pericardial involvement is the retained blood syndrome (RBS) that develops due to obstruction of chest tubes by clot that initiates vascular endothelial growth factor inflammatory response resulting in increase of tissue exudative permeability and collection of blood in pleura and pericardium. It is observed in about 13.8-22% of patients undergoing surgery and intervention for pericardial effusion and tamponade are required in about 2.7-6.4% of patients (20, 21). Its subacute form is associated with development of constrictive pericarditis in 1.2-2.0% of patients (21). RBS is defined in presence of 2 of following signs: pleural effusion/ hemothorax requiring drainage, pericardial effusion requiring drainage, re-exploration for washout of blood, interventions for postoperative pericardial constriction, interventions for postoperative fibrothorax.
Among factors contributing to the development of constrictive component, drying of pericardium and chemical exposure might destroy normal fibrinous activity of pericardial serous tissue generating basis for development of thrombosis, adhesions and reactive fibrosis and late and immediate tamponade. Earlier studies reported that cold injury during flushing of pericardium with iced saline could stimulate fibroblasts proliferation and disruption of serous continuity (23). Use of povidone-iodine solution has not been shown to have tissue toxicity in experimental studies, but along with hemorrhage, drying procedures and using cold saline can contribute to irritation of pericardium (24).
In some severe cases there is an extensive fibrotic thickening and calcification of pericardium involving epicardium (25) and coronary vein grafts (26) buried in scarred epicardium. Specific surgical techniques as cross-hatching of epicardium have been utilized to relief signs of constriction.
Role of inflammation has been confirmed in several studies that documented increase in C-reactive protein level and interleukin 8 in patients with PPS (27, 28). In our series (17) we showed that effusion in patients undergoing VHD surgery was correlated with signs of inflammation and presence of adhesions was related to the number of re-operations.
Another factor that can contribute to the development of late tamponade is an abnormal reaction to anticoagulant therapy in patients after VHD surgery with 2-3 fold increase in INR levels (6.0-9.0) and its association with development of late tamponade after surgery even in the absence of anticoagulant therapy (29-32).
Thus mechanical (trauma) and chemical, cold pericardial injury during cardiac operations, surgical technique, and inflammation, bleeding and abnormal reaction to anticoagulation therapy are main factors underlying development of pericardial thickening, thrombosis, fibrosis, adhesions, and effusion after cardiac surgery.
Treatment of effusive-constrictive postcardiotomy syndrome initially should include use of diuretics, NSAIDs and anti-inflammatory therapy to reduce inflammation and immune reaction, and facilitate reabsorption of effusion (3-5). Several studies reported satisfactory results of treatment of effusive-constrictive pericarditis after cardiac surgery with steroids (3-5, 14). It should be also noted that use of NSAIDs might be associated with high rate of side effects (9) and steroids might increase recurrence rate of effusions and complications of PPS (7, 33).
Pericardioectomy is the only effective treatment of constriction due to fibrosis and thickened pericardium. In some complicated cases with involvement of epicardium the specific techniques like cross-hatching or ``turtle cage`` are usually applied to relief epicardial constriction (11, 25, 26).
Treatment of effusion and tamponade is mainly interventional and re-exploration for bleeding is required if tamponade develops early after surgery. One should take in account that diagnosis of tamponade signs is challenging early after surgery and the clinical signs and diagnostic imaging might mislead, because effusions are usually localized and can cause hemodynamic compromise (signs of bleeding, oliguria, raise in right atrial pressure, low cardiac output) that should not delay aggressive surgical re-exploration (12). Late tamponade usually accompanied by classical signs (12) and pericardiocentesis with or without drainage is choice of treatment.
Few studies demonstrated no effect of steroids before or during surgery in prevention of PPS in children and adults (34, 35). In DECS trial, 14.5% of 4494 patients undergoing cardiac surgery with cardiopulmonary bypass developed PPS, among them 3.5% of cases were complicated by tamponade. Intraoperative administration of dexamethasone failed to prevent development of PPS. In another randomized study, prophylactic use of methylprednisolone pre-cardiopulmonary bypass revealed no difference in the incidence of PPS between groups receiving methylprednisolone and saline; however, complications of PPS in form of tamponade were significantly higher in a group of methylprednisolone (30). In a posthoc analysis of DECS trial use of dexamethasone 1 mg/kg iv versus placebo increased risk of re-thoracotomy due to tamponade by 1.84 times (95% CI 1.3-2.61, p<0.001) (33).
On the other hand, Sevuk et al. (36) reported a 20% (OR 0.8, 95%CI 0.25-0.91, p<0.026) absolute reduction of PPS risk after a single intraoperative dose of 1 mg/kg of methylprednisolone in patients undergoing coronary artery bypass surgery.
It is not clear whether it is a class effect of steroids or the type of operation, with increased risk of tamponade in patients undergoing valve surgery receiving corticosteroids. It should be taken in account that abnormal reaction to anticoagulation can also contribute to development of bleeding and pericardial involvement (29-32).
Promising results have been reported for use of colchicine (8). In a COPPS double-blind randomized trial, 360 patients were allocated into 2 arms- 180 patients receiving placebo and 180 patients receiving colchicine - 1mg twice daily 1st day after surgery and then 0.5 mg twice daily 30 days after surgery in patients >70 kg and half dose for patients <70 kg. Follow-up was 12 months. Primary endpoint was PPS, and secondary composite endpoint included re-hospitalization, constrictive pericarditis, tamponade and relapse of pericardial disease. Patients in colchicine arm developed less PPS (8.9% vs 21.1%, p=0.002) and had significantly fewer secondary composite endpoint (0.6% vs 5.9%, p=0.024). Side effects occurrence did not differ between both arms. Patients on colchicine therapy had significantly better survival free of PPS as compared to placebo group. Colchicine was found to be effective in prevention of PPS and its complications in patients undergoing cardiac surgery.
Recent meta-analysis (37) of 4 randomized controlled trials (894 pts) on prevention of PPS including 2 – colchicine studies, 1- methylprednisolone and 1 - aspirin demonstrated (Fig. 1) that colchicine (2 studies 227 pts) reduced development of PPS by 62% (OR- 0.38, 95% CI 0.22-0.65), while no effect was found for methylprednisolone or aspirin.
ESC/ EACTS recommends use of colchicine after cardiac surgery for prevention of PPS in weight-adjusted doses (i.e. 0.5 mg once for patients ≤ 70 kg and 0.5 mg twice daily for patients 70 kg) and without a loading dose if there are no contraindications and it is tolerated with duration of preventive treatment for 1 month (9).
Figure 1. Forest plot for risk of postpericardiotomy syndrome summarizes and compares postpericardiotomy syndrome outcome in groups of with and without preventive treatment.
(Reproduced with permission of Elsevier Copyright 2011 from Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick DH, Adler Y. Meta-Analysis of Randomized Trials Focusing on Prevention of the Postpericardiotomy Syndrome. Am J Cardiol 2011; 108: 575–9.)
Directions for future research
Overall, there is a need for studies with a larger number of patients on intraoperative and clinical predictors and outcomes of postpericardiotomy syndrome with and without constriction and ways of prevention of its complications.
Postpericardiotomy syndrome develops in about 1/3 of patients undergoing cardiac surgery. Though causes are not yet well-defined operative technique, pericardial injury and inflammation may play role. The prognosis when timely treated is usually favorable, however complications like tamponade and constriction may occur. If patient develops classic signs of PPS with effusion early after surgery, the recommended treatment includes treatment with nonsteroidal anti-inflammatory agents, steroids and diuretics. In case of large effusion and tamponade pericardiocentesis is indicated. In case of constrictive pericarditis after surgery, pericardiotomy is indicated. For prevention of PPS, colchicine is shown to be effective.
Peer-review: External and internal
Conflict of interest: None to declare
Acknowledgment and funding: None to declare.